OSR Health (OSRHW) Income from Continuing Operations (2022 - 2026)
OSR Health (OSRHW) posted Income from Continuing Operations of 3467174.08 for Q1 2026, up 52.15% sequentially from 7245655.0 in Q4 2025, and up 69.57% YoY from 2044722.08 in Q1 2025.
OSR Health (OSRHW) Income from Continuing Operations (2022 - 2026) Analysis & Trends
OSR Health has reported Income from Continuing Operations for 5 years, with the latest figure at 3467174.08 in Q1 2026.
- Quarterly Income from Continuing Operations rose 69.57% year-over-year to 3467174.08 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 19132901.08 (down 4.17% YoY) and the FY2025 annual result came in at 27058541.0, down 161.97% from the prior year.
- Income from Continuing Operations climbed to 3467174.08 in Q1 2026 per OSRHW's latest filing, from 7245655.0 in the prior quarter.
- Over five years, Income from Continuing Operations peaked at 301464.0 in Q2 2023 and troughed at 11392814.05 in Q1 2025.
- A 5-year average of 2530381.76 and a median of 1808505.5 in 2024 frame the typical range for Income from Continuing Operations.
- The sharpest annual moves came in 2023 and 2024: Income from Continuing Operations jumped 30612.55% in 2023, then sank 4393.18% in 2024.
- Over 5 years, Income from Continuing Operations stood at 14252.0 in 2022, then plunged by 504.63% to 86172.0 in 2023, then slumped by 1454.48% to 1339523.0 in 2024, then tumbled by 440.91% to 7245655.0 in 2025, then soared by 52.15% to 3467174.08 in 2026.
- According to Business Quant data, Income from Continuing Operations over the past three periods registered 3467174.08, 7245655.0, and 3194874.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.12 Bn | 131.27 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.30 Bn | 77.31 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 62.84 Bn | 57.66 Bn | 1.37 Bn | 482.00 Mn |
| 4 | Moderna | 55.67 Bn | 50.53 Bn | 52.00 Mn | -782.00 Mn |
| 5 | BeOne Medicines | 41.43 Bn | 36.33 Bn | 1.53 Bn | 237.01 Mn |
| 6 | Alnylam Pharmaceuticals | 31.70 Bn | 28.39 Bn | 992.69 Mn | 164.49 Mn |
| 7 | BioNTech SE | 27.47 Bn | 9.08 Bn | 668.28 Mn | -174.37 Mn |
| 8 | Royalty Pharma | 27.16 Bn | 26.33 Bn | - | 81.49 Mn |
| 9 | Insmed | 27.03 Bn | 25.87 Bn | 358.27 Mn | -13.27 Mn |
| 10 | OSR Health | 1.40 Mn | 20.39 Mn | 86,605.00 | -1.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -3.47 Mn |
| Dec 31, 2025 | -7.25 Mn |
| Sep 30, 2025 | -3.19 Mn |
| Jun 30, 2025 | -5.23 Mn |
| Mar 31, 2025 | -11.39 Mn |
| Dec 31, 2024 | -1.34 Mn |
| Sep 30, 2024 | -3.36 Mn |
| Jun 30, 2024 | -2.28 Mn |
| Mar 31, 2024 | -3.36 Mn |
| Dec 31, 2023 | -86,172.00 |
| Sep 30, 2023 | 78,183.00 |
| Jun 30, 2023 | 301,464.00 |
| Mar 31, 2023 | 110,305.00 |
| Dec 31, 2022 | -14,252.00 |
| Sep 30, 2022 | -20,022.00 |
| Jun 30, 2022 | -988.00 |